The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis
The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, S...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/10/1101 |
| _version_ | 1797513010371100672 |
|---|---|
| author | Danielle Soares de Oliveira Daian e Silva Flávio Guimarães da Fonseca |
| author_facet | Danielle Soares de Oliveira Daian e Silva Flávio Guimarães da Fonseca |
| author_sort | Danielle Soares de Oliveira Daian e Silva |
| collection | DOAJ |
| description | The COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, SARS-CoV-2. Among all the vaccine strategies put into play for study and validation, those based on recombinant viral vectors gained special attention due to their effectiveness, ease of production and the amplitude of the triggered immune responses. Some of these new vaccines have already been approved for emergency/full use, while others are still in pre- and clinical trials. In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson & Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others. |
| first_indexed | 2024-03-10T06:09:41Z |
| format | Article |
| id | doaj.art-a452f963a7064b2a880f46812888955d |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T06:09:41Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-a452f963a7064b2a880f46812888955d2023-11-22T20:15:09ZengMDPI AGVaccines2076-393X2021-09-01910110110.3390/vaccines9101101The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global CrisisDanielle Soares de Oliveira Daian e Silva0Flávio Guimarães da Fonseca1Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilLaboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, BrazilThe COVID-19 pandemic represents a milestone in vaccine research and development in a global context. A worldwide effort, as never seen before, involved scientists from all over the world in favor of the fast, accurate and precise construction and testing of immunogens against the new coronavirus, SARS-CoV-2. Among all the vaccine strategies put into play for study and validation, those based on recombinant viral vectors gained special attention due to their effectiveness, ease of production and the amplitude of the triggered immune responses. Some of these new vaccines have already been approved for emergency/full use, while others are still in pre- and clinical trials. In this article we will highlight what is behind adeno-associated vectors, such as those presented by the immunogens ChaAdOx1, Sputnik, Convidecia (CanSino, Tianjin, China), and Janssen (Johnson & Johnson, New Jersey, EUA), in addition to other promising platforms such as Vaccinia virus MVA, influenza virus, and measles virus, among others.https://www.mdpi.com/2076-393X/9/10/1101vaccineSARS-CoV-2COVID-19recombinant viral vectorsimmunization |
| spellingShingle | Danielle Soares de Oliveira Daian e Silva Flávio Guimarães da Fonseca The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis Vaccines vaccine SARS-CoV-2 COVID-19 recombinant viral vectors immunization |
| title | The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis |
| title_full | The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis |
| title_fullStr | The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis |
| title_full_unstemmed | The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis |
| title_short | The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis |
| title_sort | rise of vectored vaccines a legacy of the covid 19 global crisis |
| topic | vaccine SARS-CoV-2 COVID-19 recombinant viral vectors immunization |
| url | https://www.mdpi.com/2076-393X/9/10/1101 |
| work_keys_str_mv | AT daniellesoaresdeoliveiradaianesilva theriseofvectoredvaccinesalegacyofthecovid19globalcrisis AT flavioguimaraesdafonseca theriseofvectoredvaccinesalegacyofthecovid19globalcrisis AT daniellesoaresdeoliveiradaianesilva riseofvectoredvaccinesalegacyofthecovid19globalcrisis AT flavioguimaraesdafonseca riseofvectoredvaccinesalegacyofthecovid19globalcrisis |